Geno­cea shelves its lead drug, slash­es staff and switch­es fo­cus to trendy neoanti­gens

Neoanti­gens are a hot com­mod­i­ty right now in the siz­zling im­muno-on­col­o­gy field, and that looks too at­trac­tive for Geno­cea to pass up on.

The biotech $GN­CA says it is shelv­ing work on its lead, Phase III-ready pro­gram for gen­i­tal her­pes, putting it up for auc­tion as it slash­es 40% of its staff and re­fo­cus­es the com­pa­ny.

Geno­cea had 87 staffers at the end of last year, which will trans­late in­to about 35 em­ploy­ees los­ing their jobs.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER